Allowing compounding pharmacies to circumvent the intellectual property of innovative companies and sell potentially unsafe or less effective versions of these drugs jeopardizes patients’ safety and disincentivizes continued innovation in the pharmaceutical industry.
The new class of GLP-1 medicines exemplifies both the potential of pharmaceutical innovation and the risks to future advancements from ill-considered government policies.
The incredible benefits from GLP-1’s are clear – they significantly improve our health and well-being.
Risks arise because current federal policies enable activities that jeopardize patient safety and undermine innovators’ ability to cover their large, private capital costs.
Nothing contained in this blog is to be construed as necessarily reflecting the views of the Pacific Research Institute or as an attempt to thwart or aid the passage of any legislation.
The Compounding Pharmacy Loophole Threatens Safety And Innovation
Wayne H Winegarden
Allowing compounding pharmacies to circumvent the intellectual property of innovative companies and sell potentially unsafe or less effective versions of these drugs jeopardizes patients’ safety and disincentivizes continued innovation in the pharmaceutical industry.
The new class of GLP-1 medicines exemplifies both the potential of pharmaceutical innovation and the risks to future advancements from ill-considered government policies.
The incredible benefits from GLP-1’s are clear – they significantly improve our health and well-being.
Risks arise because current federal policies enable activities that jeopardize patient safety and undermine innovators’ ability to cover their large, private capital costs.
Read the op-ed here.
Nothing contained in this blog is to be construed as necessarily reflecting the views of the Pacific Research Institute or as an attempt to thwart or aid the passage of any legislation.